Literature DB >> 3093208

Antiepileptic effects of a calcium antagonist (nimodipine) on cefazolin-induced epileptogenic foci in rabbits.

C Morocutti, F Pierelli, L Sanarelli, E Stefano, A Peppe, G L Mattioli.   

Abstract

The epileptogenic properties of cefazolin (CFZ) were utilized to induce an electrophysiological pattern of epilepsy in the rabbit. CFZ, cortically applied in different concentrations (2 or 4%), produced epileptic activity in a degree proportional to the concentration of the substance. In this experimental epilepsy model, we evaluated the effects of increasing doses (0.025, 0.05, and 0.1 mg/kg i.v.) of the calcium antagonist nimodipine (Bay e 9736). In the evaluation of nimodipine effects, the spike-and-wave burst frequency per minute was taken into account. These data were compared with those of placebo-treated (Bay e 9736 control test) control groups and statistically evaluated by two-tailed t test. In 2% CFZ-induced epilepsy, nimodipine at the 0.025- and 0.05-mg/kg doses did not produce significant changes in the EEG pattern. A statistically significant reduction (p less than 0.001) in epileptic activity was observed at the 0.1-mg/kg nimodipine dose. This reduction was seen first in the contralateral focus leads and persisted for the entire time of observation. In the more intense epileptic form (4% CFZ), nimodipine at the doses employed did not induce noteworthy EEG modifications. These data indicate that nimodipine exerts an antiepileptic effect. The possible mechanisms involved in this activity of a calcium antagonist are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3093208     DOI: 10.1111/j.1528-1157.1986.tb03574.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  7 in total

Review 1.  Psychopharmacological properties of calcium channel inhibitors.

Authors:  O Pucilowski
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Cromakalim (BRL 34915) counteracts the epileptiform activity elicited by diltiazem and verapamil in rats.

Authors:  P Popoli; A Pezzola; S Sagratella; Y C Zeng; A Scotti de Carolis
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

3.  Effects of Ca2+ antagonists on glutamate release and Ca2+ influx in the hippocampus with in vivo intracerebral microdialysis.

Authors:  Y M Lu; J T Zhang; F Q Zhao; Y F Qin
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

4.  Nifedipine for epilepsy? A pilot study.

Authors:  J G Larkin; E Butler; M J Brodie
Journal:  Br Med J (Clin Res Ed)       Date:  1988-02-20

5.  Synergistic anticonvulsant effects of pregabalin and amlodipine on acute seizure model of epilepsy in mice.

Authors:  Itefaq Hussain Qureshi; Azra Riaz; Rafeeq Alam Khan; Afaq Ahmed Siddiqui
Journal:  Metab Brain Dis       Date:  2017-03-09       Impact factor: 3.584

6.  Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients.

Authors:  A Tartara; C A Galimberti; R Manni; L Parietti; C Zucca; H Baasch; L Caresia; W Mück; N Barzaghi; G Gatti
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

7.  Evidence for verapamil-induced functional inhibition of noradrenergic neurotransmission in vivo.

Authors:  S Gurtu; S Seth; A K Roychoudhary
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.